Glaucoma, Angle-Closure
Conditions
Keywords
Side effects, Topiramate
Brief summary
We test the hypothesis whether topiramate narrows the angles which may render Asians more likely to suffer from acute angle closure glaucoma.
Detailed description
Topiramate is approved for the treatment of epilepsy and prophylaxis of migraine attacks. There were case reports of acute angle closure glaucoma (AACG) associated with its use. AACG is particularly common in Asians because of a higher prevalence of narrow angle., we test the hypothesis whether topiramate narrows the angles which may render them more likely to suffer from AACG.
Interventions
DRUGTopiramate
Sponsors
Hong Kong Eye Hospital
Chinese University of Hong Kong
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Participants aged 18-75 with an indication for starting topiramate.
Exclusion criteria
* Patients with known allergy or intolerance to topiramate. * Recent exposure to topiramate (\<3 months). * Moderate to severe renal failure. * Known history of renal calculi or hepatic failure * Inability to give informed consent. * Pregnant women or women of child-bearing age who do not practise an acceptable means of contraception. * Patients known to have angle-closure glaucoma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change(s) in ophthalmic parameters measured at baseline and after 4 weeks of treatment, including: | 4 weeks |
| best-corrected visual acuity, refraction, Goldmann applanation tonometry, Gonioscopy, dilated fundus examination, | 4 weeks |
| and ultrasound biomicroscopy of angle and anterior segment. | 4 weeks |
Countries
Hong Kong
Outcome results
None listed